Log in

NASDAQ:CYCNCyclerion Therapeutics Stock Price, Forecast & News

-0.40 (-6.91 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $5.39
50-Day Range
MA: $3.86
52-Week Range
Now: $5.39
Volume385,238 shs
Average Volume188,248 shs
Market Capitalization$149.57 million
P/E RatioN/A
Dividend YieldN/A
There is no company description available for Cyclerion Therapeutics Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CYCN



Sales & Book Value

Annual Sales$4.51 million
Book Value$3.56 per share


Net Income$-123,010,000.00
Net Margins-1,917.30%


Market Cap$149.57 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive CYCN News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.

Cyclerion Therapeutics (NASDAQ:CYCN) Frequently Asked Questions

How has Cyclerion Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Cyclerion Therapeutics' stock was trading at $2.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CYCN stock has increased by 85.9% and is now trading at $5.39. View which stocks have been most impacted by Coronavirus.

When is Cyclerion Therapeutics' next earnings date?

Cyclerion Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Cyclerion Therapeutics.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics Inc (NASDAQ:CYCN) announced its quarterly earnings data on Monday, May, 4th. The company reported ($0.73) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.14. The firm earned $1.01 million during the quarter. Cyclerion Therapeutics had a negative net margin of 1,917.30% and a negative return on equity of 96.31%. View Cyclerion Therapeutics' earnings history.

Has Cyclerion Therapeutics been receiving favorable news coverage?

News articles about CYCN stock have been trending neutral on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cyclerion Therapeutics earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutCyclerion Therapeutics.

Are investors shorting Cyclerion Therapeutics?

Cyclerion Therapeutics saw a decline in short interest in April. As of April 30th, there was short interest totaling 1,300,000 shares, a decline of 13.3% from the April 15th total of 1,500,000 shares. Based on an average trading volume of 406,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 5.5% of the company's shares are short sold. View Cyclerion Therapeutics' Current Options Chain.

Who are some of Cyclerion Therapeutics' key competitors?

What other stocks do shareholders of Cyclerion Therapeutics own?

What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Who are Cyclerion Therapeutics' major shareholders?

Cyclerion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include MFN Partners Management LP (8.75%), BlackRock Inc. (5.73%), State Street Corp (1.94%), AWH Capital L.P. (1.17%), Geode Capital Management LLC (1.16%) and AQR Capital Management LLC (0.59%). Company insiders that own Cyclerion Therapeutics stock include Amy W Schulman, Andreas Busch, Mark G Currie and William Huyett. View institutional ownership trends for Cyclerion Therapeutics.

Which institutional investors are selling Cyclerion Therapeutics stock?

CYCN stock was sold by a variety of institutional investors in the last quarter, including AWH Capital L.P., Horizon Kinetics Asset Management LLC, BlackRock Inc., New York State Common Retirement Fund, Alambic Investment Management L.P., UBS Group AG, and First Trust Advisors LP. Company insiders that have sold Cyclerion Therapeutics company stock in the last year include Mark G Currie, and William Huyett. View insider buying and selling activity for Cyclerion Therapeutics.

Which institutional investors are buying Cyclerion Therapeutics stock?

CYCN stock was purchased by a variety of institutional investors in the last quarter, including MFN Partners Management LP, Sphera Funds Management LTD., Invesco Ltd., Ensign Peak Advisors Inc, Geode Capital Management LLC, Parametric Portfolio Associates LLC, AQR Capital Management LLC, and Wells Fargo & Company MN. Company insiders that have bought Cyclerion Therapeutics stock in the last two years include Amy W Schulman, Andreas Busch, and Mark G Currie. View insider buying and selling activity for Cyclerion Therapeutics.

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $5.39.

How big of a company is Cyclerion Therapeutics?

Cyclerion Therapeutics has a market capitalization of $149.57 million and generates $4.51 million in revenue each year.

What is Cyclerion Therapeutics' official website?

The official website for Cyclerion Therapeutics is www.cyclerion.com.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.